DiscoverBlood & CancerNCI-MATCH trial reveals actionable mutations and matches cancer patients to targeted therapies
NCI-MATCH trial reveals actionable mutations and matches cancer patients to targeted therapies

NCI-MATCH trial reveals actionable mutations and matches cancer patients to targeted therapies

Update: 2021-02-11
Share

Description

The NCI-MATCH trial was designed to reveal mutations in underexplored cancer types, allowing researchers to match patients to appropriate targeted therapies.

Study investigator Alice P. Chen, MD, from the National Cancer Institute, reviews the goals and results of NCI-MATCH with host David H. Henry, MD, in this episode.

Trial details

  • NCI-MATCH has more than 1,000 participating sites.
  • The trial is open to patients with advanced cancers that have progressed on standard treatment or rare cancers for which there is no standard treatment.
  • Investigators use next-generation sequencing to identify mutations in tumor biopsies taken before the start of therapy.
  • Sequencing is performed at MD Anderson Cancer Center, Houston; Massachusetts General Hospital, Boston; MoCha at NCI’s Frederick (Md.) National Lab; Yale University, New Haven, Conn.; and commercial labs.

Matching patients to treatment

  • When a patient is found to have an actionable mutation, that patient is assigned to an investigational treatment, typically monotherapy.
  • A patient cannot be assigned to a treatment that is already known to be effective against their cancer; for example, patients with BRAF-mutated melanoma were excluded.
  • The NCI’s Cancer Therapy Evaluation Program sends the patient's targeted therapy to the participating site within 24 hours of notification.
  • CT imaging is done prior to the start of treatment, and patients are monitored with repeat scans every two cycles.

Results

Future directions

Show notes written by Sheila DeYoung, DO, a resident at Pennsylvania Hospital, Philadelphia.

Disclosures

Dr. Chen and Dr. Henry have no conflicts of interest.

*  *  *

For more MDedge Podcasts, go to www.mdedge.com/podcasts

Email the show: podcasts@mdedge.com

Interact with us on Twitter: @MDedgehemonc

David Henry on Twitter: @davidhenrymd

Comments 
In Channel
loading
Download from Google Play
Download from App Store
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

NCI-MATCH trial reveals actionable mutations and matches cancer patients to targeted therapies

NCI-MATCH trial reveals actionable mutations and matches cancer patients to targeted therapies

Medscape Professional Network